Cancer Registry Software Market Size - By Product Type (Standalone, Integrated), Delivery Mode (On-premise, Cloud-based), Database (Commercial, Public), Functionality (Cancer Reporting, Patient Care Management), End-user, Global Forecast (2023 - 2032)
Published Date: August - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationCancer Registry Software Market Size - By Product Type (Standalone, Integrated), Delivery Mode (On-premise, Cloud-based), Database (Commercial, Public), Functionality (Cancer Reporting, Patient Care Management), End-user, Global Forecast (2023 - 2032)
Cancer Registry Software Market Size
Cancer Registry Software Market size accounted for USD 71.4 million in 2022 and is estimated to grow at a CAGR of 10.5% to reach USD 193.4 million by 2032 attributed to the factors including rising cancer prevalence, increasing government initiatives for cancer treatment, growing adoption of EHR, and increasing emphasis on evidence-based medicine.
The information gathered with the aid of cancer registry software aids in the development of therapeutics for the treatment of cancer by researchers and medical professionals and helps in preventing the global spread of diseases. The government can track the patients in a specific area and location with the aid of this software.
In August 2021, the researchers from the International Agency for Research on Cancer IARC, the Northern Ireland Cancer Registry, and the Union for International Cancer Control (UICC) launched new software to facilitate cancer staging. Additionally, in October 2020, MOVEMBER launched the largest network of prostate cancer patient registries in world. By leveraging the 'real world' experiences of more than 130,000 men, this network will have the power to revolutionise the treatment and care of the disease. This initiative provides a more efficient and affordable digital solution, which enhances the infrastructure and lowers costs.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Cancer Registry Software Market Size in 2022 | USD 71.4 Million |
| Forecast Period | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR | 10.5% |
| 2032 Value Projection | USD 193.4 Million |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 175 |
| Tables, Charts & Figures | 306 |
| Segments covered | Product Type, Delivery Mode, Database, Functionality, End-User, and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
COVID-19 Impact Analysis
Hey there, remember those chaotic days during the pandemic? Medical care for cancer took a big hit. Screenings, chemo, and surgeries were all put on hold. This meant fewer cancer diagnoses and those who were diagnosed couldn't get the treatment they needed right away. Hospitals and clinics had a tough time keeping track of who had cancer and how many new cases were popping up. It's like they were in a fog, struggling to keep count. The pandemic made one thing crystal clearhealthcare systems need to work together like a well-oiled machine. When hospitals and doctors can share information online, it's like peeling back a layer of fog. They can track cancer cases better and make sure everyone is getting the care they deserve. Think about it. Cancer registry software that can talk to other healthcare systems is the key to solving this puzzle. It's like having a supercomputer that can keep all the data organized and up-to-date. This way, every patient can get the care they need, when they need it.
Cancer Registry Software Market Driving Factors
Imagine if cancer healthcare professionals had a digital helping hand. There's cancer registry software that's like a watchful guardian, keeping a close eye on the journeys of cancer patients. And it's a crucial tool because the numbers are staggering. In 2020, the World Health Organization reported nearly 20 million new cases of cancer worldwide. By 2040, that's expected to jump almost 50% to over 30 million. And here's the sobering partthe International Agency for Research on Cancer estimates that cancer-related deaths could reach 16.3 million by 2040. Faced with these overwhelming odds, cancer registry software becomes a lifeline. It's a tool that helps healthcare providers track cancer trends, pinpoint potential risks, and customize treatment plans for each patient. It's a tool that gives us hope, a way to fight back against this disease and make a real difference for those who need it most.
Cancer Registry Software Market Analysis
Based on product type, the cancer registry software market is segmented into standalone software and integrated software. The standalone software segment will grow at 10% CAGR to reach USD 143.7 million by 2032.The standalone software is cost-effective, flexible, provides easy integration and data security. The use of standalone software is increasing in the healthcare industry mainly due to the industry’s changing landscape, the need to streamline and optimize workflows and decrease physician workloads.
When it comes to cancer registry software, you have two optionskeep it on your own computer or use a cloud-based system. If you choose to keep it on your own computer, you'll have more control over your data and security. This is a good option for organizations that work with sensitive information, like research institutes. On-premise software also has more advanced features for managing large amounts of data. The main advantage of keeping your software on-premise is that it's more secure. Your data is stored on your own computer, so there's less chance of it being hacked. You can also set up your own security measures to protect your data further.
The cloud-based cancer registry software can be integrated with the real time data and standard guidelines. This software helps in the reduction of information technology overhead costs. In addition, the cloud-based cancer registry software is efficient in nature.
Based on database, the cancer registry software market is segmented into commercial database and public database. The commercial database segment accounted for highest market share of 72.5% in 2022. The data stored in the commercial database is quite safe as compared to public database and it can be easily tracked and used across research centres and government agencies.
The public database is used for the various cancer research programs. The utilization of public database is growing due to the increasing number of research centres all over the globe. The public database can help to track patient data from any corner of the world.
Imagine having a helper that keeps a close watch on cancer in your neighborhood. This helper, called a cancer registry software, is like a team with different roles. One group tracks every cancer case, sending information to local and national health experts. This gives us a clear picture of how many people are getting cancer and who's passing away from it. Another group helps doctors take care of their patients. They keep track of treatments, appointments, and other details. Plus, they help gather information for research, like how new drugs or treatments are working. Finally, the software helps researchers understand the impact of cancer treatments. By gathering data on how patients respond, they can figure out what works best and where we need to do better. In 2022, the part of the software that tracks cancer cases was valued at around $30 million. It's a huge deal because it helps us monitor cancer trends, leading to better patient care, more research breakthroughs, and more informed decisions about public health.
Based on end-user, the cancer registry software market is segmented into government organizations & third-party administration, research institutes, hospital & medical practices, private players, and pharmaceutical, biotech, & medical device companies. The government organizations and third-party administration segment is expected to grow at a CAGR of 10% by 2032. This software helps to track and monitor cancer patients in their respective region. In addition, the increased investments, and initiatives by government for the implementation of cancer registry software in hospitals.
The North America cancer registry software marketaccounted for market share of 51.6% in 2022. The industry in this region is growing due to the rising prevalence of cancer, well-developed healthcare infrastructure, increasing investments by government, and the growing demand for cancer registry software.
On the other hand, Asia-Pacific is anticipated to experience the fastest expansion by 2032. The governments of developing countries like China and Japan are constantly working to develop the market for cancer registry software.
Cancer Registry Software Market Share
Major market players operating in the cancer registry software market include
- Elekta
- C/NET Solutions
- Electronic Registry Systems Inc.
- Onco Inc.
- McKesson Corporation
- Siemens Healthineers
- IBM Corporation
- Ordinal data, Inc.
- Conduent, Inc.
- NeuralFrame, Inc
Cancer Registry Software Industry News
- In May 2023, Elekta announced the launch of Elekta ONE, an advanced software for oncology departments and clinics. This development strengthened company’s product portfolio and is expected to boost revenue.
- In April 2018, Elekta and PalabraApps LLC formed a partnership to create the software that runs its MOSAIQ Oncology Information System. This development helped the company to enhance their product portfolio and customer base.
The cancer registry software market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments
Click here to Buy Section of this Report
By Product Type
- Standalone software
- Integrated software
By Delivery Mode
- On-premise
- Cloud-based
By Database
- Commercial database
- Public database
By Functionality
- Cancer reporting
- Patient care management
- Medical research and clinical studies
- Product outcome evaluation
By End-User
- Government organizations and third-party administration
- Research institutes
- Hospital & medical practices
- Private payers
- Pharmaceutical, biotech, and medical device companies
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- South Africa
- Saudi Arabia
- Rest of Middle East & Africa
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy